参麦注射液对乳腺癌术后患者的血清PCT IL-6 TNF-α水平及心肌功能的影响

doi:10.3969/j.issn.1006-6233.2018.04.025

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1324 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To study the effects of Shenmai injection on serum PCT, IL-6, TNF-α and myocardial function in postoperative with breast cancer and to evaluate its effect on prognosis.. Methods: 90 patients of mammary cancer who received therapy from March 2014 to December 2016 in our hospital were selected as research objects. According to draw method were divided into the experimental group and the control group. Two groups of patients were treated with chemotherapy after operation, Intravenous infusion of cyclophosphamide, fluorouracil, epirubicin. The experimental group on this basis, was treated with Shenmai Injection, each 50ml, add 5% Glucose Injection 500ml to the intravenous drip, 1 times a day. Then the curative effect, clinical symptom score, procalcitonin (PCT) and interleukin -6 (IL-6), tumor necrosis factor alpha (TNF- alpha) levels of troponin (cTnI), creatine kinase (CK), creatine kinase (CK-MB) level, superoxide dismutase (SOD), glutathione (GSH), malondialdehyde (MDA) level of two groups were compared. Results: The total remission rate of the experimental group was significantly higher than the control group [86.66%(39/45)vs66.66%(30/45] (P＜0.05); Fatigue, sweating, dry mouth and throat, spiritlessness scores were significantly lower than the control group [(1.53±0.23) scores vs(3.10±0.63)scores, (1.40±0.32)scores vs(3.15±0.80)scores,(1.30±0.31)scores vs(3.04±0.70)scores,(1.52±0.27)scores vs(3.02±0.60)scores](P<0.05); PCT、IL-6、TNF-α level were significantly lower than the control group [(1.62±0.32)μg/L vs(5.83±1.05)μg/L,(5.72±0.98)pg/mL vs(10.89±1.52)pg/mL,(1.23±0.15)ng/mL vs(2.79±0.23)ng/mL](P<0.05); cTnI、CK、CK-MB level were significantly lower than the control group [(450.76±58.83)ng/L vs(702.17±83.18)ng/L,(1.87±0.40)IU/mL vs(5.20±1.34)IU/mL,(158.90±42.10)IU /L vs(910.38±97.94)IU /L](P<0.05); SOD, GSH level were significantly higher than the control group [(109.89±13.68)μIU /L vs(78.89±10.29)μIU /L,(140.83±20.82)μg/L vs(117.49±17.89)μg/L](P＜0.05), MDA level were significantly lower than the control group [(5.39±1.21)μmol/L vs(12.76±3.81)μmoL/L](P<0.05).Conclusion: Shenmai injection has remarkable effect on myocardial protection after operation for breast cancer patients. It can reduce the levels of inflammatory factors PCT, IL-6 and TNF- alpha, reduce the incidence of postoperative infection and benefit the prognosis of patients.

Key words： Shenmai injection Mammary cancer Myocardial function Procalcitonin Interleukin -6 Tumor necrosis factor alpha

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2018.04.025 OR http://www.hbyxzzs.cn/EN/Y2018/V24/I4/623

[1] 姚铁柱,徐志宏,马景涛,等.参麦注射液对乳腺癌患者术后化疗导致心肌损害的保护作用[J].中国实验方剂学杂志,2016,24(7):208~212.
[2] Renoux B, Raes F, Legigan T, et al. Targeting the tumour microenvironment with an enzyme-responsive drug delivery system for the efficient therapy of breast and pancreatic cancers[J]. Chem Sci, 2017, 8(5): 3427~3433.
[3] 张翔云,郭勇.乳腺癌的中西医结合治疗现状及展望[J].黑龙江中医药,2016,45(2):79~81.
[4] Klevos GA, Collado-Mesa F, Net JM, et al. Utility of supplemental screening with breast ultrasound in asymptomatic women with dense breast tissue who are not at high risk for breast cancer[J]. Indian Radiol Imaging, 2017, 27(1): 52~58.
[5] 中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2015版)[J].中国癌症杂志,2015,25(09):692.
[6] 魏荣富,金茂勇.参麦注射液联合TP化疗方案对乳腺癌术后患者的疗效观察及生存质量的影响[J].实用癌症杂志,2016,31(7):1088~1090.
[7] Lin W, Huang J, Yuan Z, et al. Protein kinase C inhibitor chelerythrine selectively inhibits proliferation of triple-negative breast cancer cells[J]. Sci Rep, 2017, 7(1): 2022~2030.
[8] 魏晓晨,朱立勤,王春革,等.参麦注射液预防恶性肿瘤化疗所致周围神经毒性效果的系统评价[J].山东医药,2016,56(28):45~47.
[9] Salerno KE. NCCN Guidelines Update: Evolving Radiation Therapy Recommendations for Breast Cancer[J].Natl Compr Canc Netw, 2017, 15(5S): 682~684.
[10] 潘改燕,张妮.参麦注射液对乳腺癌患者术后化疗导致心肌损害的保护作用[J].现代中西医结合杂志,2016,25(30):3327~3329.
[11] Gradishar WJ. New approaches to endocrine therapy for breast cancer[J].Natl Compr Canc Netw, 2017, 15(5S): 679~681.
[12] 吴玖斌,谢雁鸣,王连心,等.参麦注射液辅助治疗恶性肿瘤的有效性及安全性系统评价[J].中国中医基础医学杂志,2014,20(11):1525~1528.
[13] Schwartzberg LS. Use of Biomarkers and multigene assays in breast cancer[J].Natl Compr Canc Netw, 2017, 15(5S): 676~678.
[14] 朱亚兰,郭佳奕,包美蓉.参麦注射液辅助化疗治疗恶性肿瘤疗效的Meta分析[J].中国药房,2015,26(12):1654~1657.
[15] Zhang S, Zhang D, Gong M, et al. High lymphatic vessel density and presence of lymphovascular invasion both predict poor prognosis in breast cancer[J]. BMC Cancer, 2017, 17(1): 335~338.
[16] 李震,翟玉峰,冀叶,等.参麦注射液防治局部肿瘤放疗不良反应的临床研究[J].中药药理与临床,2015,31(04):213~215.
[17] Lagendijk M, Vos EL, Koning AHJ, et al. TUmor-volume to breast-volume RAtio for improving COSmetic results in breast cancer patients (TURACOS); a randomized controlled trial[J]. BMC Cancer, 2017, 17(1): 336~340.
[18] 王海燕.参麦注射液对乳腺癌患者术后辅助化疗减毒增效作用的临床研究[J].临床合理用药杂志,2015,8(32):58~60.